Johns Hopkins Myositis Center

Home / Our Doctors / Andrew Mammen, M.D., Ph.D.

Andrew Mammen, M.D., Ph.D.

Associate Director, Johns Hopkins Myositis Center

Investigator, National Institutes of Health

andrew-mammen-headshot-copy

 After obtaining his M.D. and Ph.D. at Johns Hopkins, Dr. Mammen completed his neurology residency and neuromuscular fellowship at the same institution. He co-founded the Johns Hopkins Myositis Center in 2007, where he and his colleagues discovered a novel form of autoimmune myopathy associated with statin use and autoantibodies recognizing HMG-CoA reductase, the pharmacologic target of statins. In 2014, Dr. Mammen moved to the NIH, where he is an Investigator and Leader of the Muscle Disease Unit. His laboratory focusses on understanding the pathological mechanisms underlying disease in dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and inclusion body myositis. In addition to seeing myositis patients at the NIH Clinical Center, he maintains an appointment as Adjunct Professor of Neurology and Medicine at Hopkins, where he continues to see patients at the Myositis Center.

  • MD: Johns Hopkins University, School of Medicine
  • PhD: Johns Hopkins University, School of Medicine
  • Internship: Johns Hopkins Hospital
  • Neurology Residency: Johns Hopkins Hospital
  • Neuromuscular Fellowship: Johns Hopkins Hospital

Publications: Peer-reviewed Original Science Research

  1. Podlisney M, Mammen A, Schlossmacher M, Palmer M, Younkin S, Selkoe D. Detection of soluble forms of the beta-amyloid precursor protein in human plasma. Biochemical and Biophysical Research Communications. 1990; 167: 1094-1101.
  2. Hirsch D, Steiner J, Dawson T, Mammen A, Hayek E, Snyder S. Neurotransmitter release regulated by nitric oxide in PC-12 cells and brain synaptosomes. Current Biology. 1993; 3: 749-754.
  3. Von Koch C, Lahiri D, Mammen A, Copeland N, Gilbert D, Jenkins N, Sisodia S. The mouse APLP2 gene: chromosomal localization and promotor characterization. The Journal of Biological Chemistry. 1995; 270: 25475-25480.
  4. Lau L-F, Mammen A, Ehlers M, Kindler S, Chung W, Garner C, Huganir R. Interaction of the N-methyl-D-aspartate receptor complex with a novel synapse-associated protein, SAP102. The Journal of Biological Chemistry. 1996; 271: 21622-21628.
  5. Roche K, O’Brien R, Mammen A, Bernhardt J, Huganir R. Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron. 1996; 16: 1179-1188.
  6. Mammen A, Kameyama K, Roche K, Huganir R. Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II. The Journal of Biological Chemistry. 1997; 272: 32528-32533.
  7. O’Brien R, Mammen A, Blackshaw S, Ehlers M, Rothstein J, Huganir R. The development of excitatory synapses in cultured spinal cord neurons. The Journal of Neuroscience. 1997; 17: 7339-7350.
  8. Mammen A, Huganir R, O’Brien R. Redistribution and stabilization of cell surface glutamate receptors during synapse formation. The Journal of Neuroscience. 1997; 17: 7351-7358.
  9. Mammen A, Casciola-Rosen L, Hall J, Christopher-Stine L, Corse A, and Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis and Rheumatism. 2009; 60: 3784-3793.
  10. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, and Christopher-Stine L. Rituximab Therapy for Myopathy Associated with Anti-Signal Recognition Particle Antibodies: A Case Series. Arthritis Care and Research. 2010; 62: 1328-34.
  11. Christopher-Stine L, Casciola-Rosen L, Hong G, Chung T, Corse A, and Mammen A. A novel autoantibody recognizing 200 and100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis and Rheumatism. 2010; 62: 2757-66.
  12. Mammen A, Chung T, Christopher-Stine L, Rosen P, Rosen A, Casciola-Rosen L. Autoantibodies against 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) in Patients with Statin-Associated Autoimmune Myopathy. Arthritis and Rheumatism. 2011; 63: 713-21.
  13. Moghekar A, Rao S, Li M, Ruben D, Mammen A, Tang X, and O’Brien RJ. Large quantities of A peptide are constitutively released during amyloid precursor protein metabolism in vivo and vitro. The Journal of Biological Chemistry. 2011; 286:15989-97.
  14. Williams KM, Ostrow LW, Loeb DM, Chung T, Cohn RD, Corse AM, Mammen A, Chen AR. Immunohistochemistry of affected tissue may guide cGVHD treatment decisions. Bone Marrow Transplant. 2011: 47(5):731-3.
  15. Mammen A, Mahoney J, St. Germain A, Badders N, Taylor J, Rosen A, Spinette S. A Novel Conserved Isoform of the Ubiquitin Ligase UFD2a/UBE4B is Expressed Exclusively in Mature Striated Muscle Cells. PLoS One. 2011;6(12):e28861.
  16. Mammen A, Pak K, Williams E, Brisson D, Coresh J, Selvin E, Gaudet D. Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculoskeletal side-effects. Arthritis Care and Research. 2012: 64(2):269-72.
  17. Mammen A, Gaudet D, Brisson D, Christopher-Stine L, Leffell S, Zachary A. Increased Frequency of DRB1*11:01 in Anti-HMG-CoA Reductase-Associated Autoimmune Myopathy. Arthritis Care and Research, 2012: 64(8):1233-7. PMID: 22422616
  18. Ostrow L, Corse A, Morrison B, Huff C, Carrino J, Hoke A, Mammen A. Expanding the Spectrum of Monoclonal Light Chain Deposition Disease in Muscle. Muscle and Nerve. 2012; 45:755-61.
  19. Casciola-Rosen L, Hall J, Mammen A, Christopher-Stine L, Rosen A. Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clinical and Experimental Rheumatology, 2012; 64:548-53. PMID: 22703875
  20. Werner J, Christopher-Stine L., Ghazarian SR, Pak K, Kus JE, Lloyd TE, and Mammen A. Antibody Levels Correlate with Creatine Kinase Levels and Strength in Anti-HMG-CoA Reductase-Associated Autoimmune Myopathy. Arthritis and Rheumatism. 2012;64:4087-93. PMID:22933019
  21. Subhawong TK, Wang X, Machado AJ, Mammen A, Christopher-Stine L, Barker PB, Carrino JA, Fayad LM. 1H Magnetic Resonance Spectroscopy Findings in Idiopathic Inflammatory Myopathies at 3 T: Feasibility and First Results. Invest Radiol. 2013: 509-16. PMID: 23563194
  22. Fiorentino D, Chung L, Christopher-Stine L, Zaba L, Li S, Mammen A, Rosen A, and Casciola-Rosen L. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1-gamma. Arthritis and Rheumatism. 2013. 65:2954-62. PMID: 24037894.
  23. De Bleecker J, Lundberg I, de Visser M, for the ENMC Myositis Muscle Biopsy Study Group, 193rd ENMC International workshop, Pathology diagnosis of idiopathic inflammatory myopathies, 30 November – 2 December 2012, Naarden, The Netherlends. Neuromuscular Disorders, 2013, 945-951. PMID: 24011698
  24. Paik J, Corse A, and Mammen A. The Co-Existence of Myasthenia Gravis in Patients with Myositis: A Case Series. Semin Arthritis Rheum. 2014, 43:792-6. PMID: 24412588.
  25. Musset L, Miyara M, Benveniste O, Charuel J-L, Shikhman A, Boyer O, Fowler R, Mammen A, Philips J, and Mahler M. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR) using different technologies. J Immunol Res. 2014;2014:405956. Epub 2014 Mar 5. PMID: 24741598
  26. Lloyd T, Mammen A, Amato A, Weiss M, Needham M, and Greenberg S. Evaluation and Construction of Diagnostic Criteria for Inclusion Body Myositis. Neurology, 2014, 83:426-33. PMID: 24975859.
  27. Sharma K, Orbai A, Desai D, Cingolani O, Halushka M, Christopher-Stine L, Mammen A, Wu K, Zakaria S. Brief Report: Antisynthetase Syndrome-Associated Myocarditis. J Card Fail, 2014, 20(12):939-45 PMID: 25084215
  28. Johnson C, Connors GR, Oaks J, Han S, Truong A, Richardson B, Lechtzin N, Mammen A, Casciola-Rosen L, Christopher-Stine L, Danoff SK. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med, 2014, 108(10):1542-8. PMID: 25269710.
  29. Roda R, Schindler A, Blackstone C, Mammen A, Corse A, and Lloyd T. Laing distal myopathy pathologically resembling inclusion body myositis. Ann Clin Transl Neurol. 2014. 1(12):1053-8. PMID: 25574480.
  30. Mohassel P, Rosen P, Casciola-Rosen L, Pak K, and Mammen A. Expression of the   dermatomyositis autoantigen transcription intermediary factory 1 in regenerating muscle. Arthritis Rheumatol. 2015, 67(1):266-72. PMID: 25186009.
  31. De Bleecker JL, De Paepe B, Aronica E, de Visser M; ENMC Myositis Muscle Biopsy Study Group, Amato A, Aronica E, Benveniste O, De Bleecker J, de Boer O, De Paepe B, de Visser M, Dimachkie M, Gherardi R, Goebel HH, Hilton-Jones D, Holton J, Lundberg IE, Mammen A, Mastaglia F, Nishino I, Rushing E, Daa Schroder H, Selcen D, Stenzel W. 205th ENMC International Workshop: Pathology diagnosis of idiopathic inflammatory myopathies Part II 28-30 March 2014, Naarden, The Netherlands. Neuromuscul Disord, 2015, 25(3):268-72. PMID: 25572016.
  32. Ramanathan S, Langguth D, Hardy T, Garg N, Bundell C, Rojana-udomsart A, Dale R, Robertson T, Mammen A, and Reddel S. Clinical course and treatment of anti-HMGCR antibody associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm. 2015 Apr 2;2(3):e96
  33. Chung T, Christopher-Stine L, Paik J, Corse A, Mammen A. The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy. Muscle Nerve. 2015, 52(2):189-95.
  34. Lloyd T, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, Danoff S, Pak K, Casciola-Rosen L, and Mammen A. Cytosolic 5’-nucleotidase 1A is a common target of circulating autoantibodies in several autoimmune diseases. Arthritis Care and Research. Epub ahead of print, 2015. PMID: 25892010.
  35. Pinal-Fernandez I, Casciola-Rosen L, Christopher-Stine L, Corse A, and Mammen A. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from dermatomyositis patients. J Rheumatol. 2015, 42(8):1448-54. PMID: 26443871.
  36. Paik J, Wigley F, Lloyd T, Corse A, Casciola-Rosen L, Shah A, Boin F, Hummers L, and Mammen A. The spectrum of muscle histopathologic findings in 42 weak scleroderma patients. Arthritis Care Res (Hoboken). 2015, 67(10):1416-25. PMID: 25989455.
  37. Mammen A and Tiniakou E. Intravenous Immunoglobulin for Statin-Triggered Autoimmune Myopathy. N Engl J Med. 2015, 373(17):1680-2. PMID: 26488714.
  38. 38. Fiorentino D, Presby M, Baer A, Petri M, Rieger K, Soloski M, Rosen A, Mammen A, Christopher-Stine L, and Casciola-Rosen L. PUF60:  a prominent new target of the autoimmune response in dermatomyositis and Sjögren’s syndrome. Annals of Rheumatic Disease (Epub ahead of print 2015). PMID: 26253095.
  39. Mammen A, Casciola-Rosen L, Lloyd T, Christopher-Stine L, and Wagner, K. Myositis specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurol Neuroimmunol Neuroinflamm. 2015;2:e172. PMID: 26668818
  40. Li W, Lee M-H, Henderson L, Tyagi R, Bachani M, Steiner J, Campanac E, Hoffman D, Geldern G, Johnson K, Maric D, Morris H, Lentz M, Pak K, Mammen A, Ostrow L, Rothstein J, and Nath A. Human endogenous retrovirus-K induces motor neuron disease. Sci Transl Med. 2015;7(307): 307ra153. PMID: 26424568.
  41. Paik J, Mammen A, Wigley, F, Shah A, Hummers L, and Polydefkis M. Symptomatic and electrodiagnostic features of peripheral neuropathy in scleroderma. Arthritis Care Res (Epub ahead of print, 2015). PMID: 26663579.
  42. Khoshnoodi M, Truelove S, Z. Burakgazi AZ, Ahmet Hoke, Mammen A, and Polydefkis M. Longitudinal assessment of small fiber neuropathy: evidence for a non-length-dependent distal axonopathy. JAMA Neurology (Epub ahead of print 2016).
  43. Floyd J, Brody J, Tiniakou E, Psaty B, and Mammen A. Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy. Muscle and Nerve. 2016:142-144.
  44. Pinal-Fernandez I*, Parks C*, Werner JL, Albayda J, Paik J, Danoff S, Casciola-Rosen L, Christopher-Stine L, and Mammen AL. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 2016 (Epub ahead of print). (*contributed equally.)
  45. Johnson C, Pinal Fernandez I, Parikh R, Paik J, Albayda J, Mammen A, Christopher-Stine L, Danoff S. Assessment of Mortality in Autoimmune Myositis with and without Associated Interstitial Lung Disease. Lung. 2016 (Epub ahead of print).
  46. Benveniste O, Rider LG; Aggarwal R, Allenbach Y, De Bleecker JL, de Groot I, Devilliers H, Hilton-Jones D, Hogrel JY, Lundberg IE, Mammen AL, Oakley, Oddis C, Padberg G, Ponce D, Rose MR, Sanner H, Selva-O’Callaghan A, de Visser M, Wells A, Werth VP. 213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. Neuromuscul Disord. 2016 May 27. [Epub ahead of print]
  47. Basharat P, Lahouti AH, Paik JJ, Albayda J, Pinal-Fernandez I, Bichile T, Lloyd TE, Danoff SK, Casciola-Rosen L, Mammen AL, Christopher-Stine L. Statin-induced anti-HMGCR-associated myopathy. J Am Coll Cardiol. 2016, 68:234-35.
  48. Musset L, Allenbach Y, Benveniste O, Boyer O, Bossuyt X, Bentow C, Phillips J, Mammen A, Van Damme P, Westhovens R, Ghirardello A, Doria A, Choi MY, Fritzler MJ, Schmeling H, Muro Y, García-De La Torre I, Ortiz-Villalvazo MA, Bizzaro N, Infantino M, Imbastaro T, Peng Q, Wang G, Vencovský J, Klein M, Krystufkova O, Franceschini F, Fredi M, Hue S, Belmondo T, Danko K, Mahler M. Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmun Rev. 2016 (Epub ahead of print).
  49. Pinal-Fernandez I*, Casal-Dominguez M*, Carrino JA, Lahouti AH, Basharat P, Albayda J, Paik JJ, Ahlawat S, Danoff SK, Lloyd TE, Mammen AL*, Christopher-Stine L*. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis. 2016 (Epub ahead of print). (*contributed equally.)
  50. Tiniakou E*, Pinal-Fernandez I*, Lloyd TE, Albyda M, Paik J, Werner JL, Casciola-Rosen L, Christopher-Stine L, and Mammen AL. More Severe Disease and Slower Recovery in Younger Patients with Anti-3-Hydroxy-3-Methylglutaryl-Conezmyme A Reductase-Associated Autoimmune Myopathy. Rheumatology (accepted for publication 2016).
  51. Kishi T*, Rider LG*, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, and Mammen AL for the Childhood Myositis Heterogeneity Study Group. Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients. Arthritis Care and Research (accepted 2016). (*contributed equally.)

Review Articles

  1. Selkoe D, Podlisny MB, Gronbeck A, Mammen A, Kosik KS. Molecular relation of amyloid filaments and paired helical filaments in Alzheimer’s disease. Advances in Neurology. 1990; 51:171-179.
  2. Ehlers M, Mammen A, Lau L-F, Huganir R. Synaptic targeting of glutamate receptors. Current Opinion in Cell Biology. 1996; 8: 484-489.
  3. Mammen A, Kamboj S, Huganir R. Protein phosphorylation of ligand-gated ion channels. Methods in Enzymology. 1999; 294: 353-370.
  4. Mammen A. Dermatomyositis and Polymyositis: Clinical Presentation, Autoantibodies, and Pathogenesis. Annals of the New York Academy of Sciences. 2009; 1184:134-153 (2009).
  5. Mammen A and Amato AA. Statin Myopathy: A review of recent progress. Current Opinion in Rheumatol 2010; 22: 644-650.
  6. Mammen A. The Autoimmune Myopathies: Autoantibodies, Distinct Clinical Phenotypes, and Pathogenesis. Nature Reviews Neurology. 2011; 7:343-354.
  7. Del Grande F, Carrino J, Del Grande M, Mammen A, and Christopher-Stine, L. Magnetic Resonance Imaging of Inflammatory Myopathies. Topics in Magnetic Resonance Imaging. 2011; 22: 39-43
  8. Casciola-Rosen L and Mammen A. Myositis Autoantibodies. Current Opinion in Rheumatology. 2012; 24:602-8. PMID: 22955022
  9. Mohassel P, Mammen A. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve. 2013 Oct;48(4):477-83. PMID: 23519993
  10. Mohassel P, Mammen A. The Spectrum of Statin Myopathy. Curr Opin Rheumatol. 2013 Nov;25(6):747-52. PMID: 24061077
  11. Mammen A. Toxic Myopathies. Continuum. 2013 Dec;19 (6 Muscle Disease):1634-49. PMID: 24305451
  12. Paik J, Mammen A, Wigley F, Gelber A. Myopathy in scleroderma, its identification, prevalence, and treatment: lessons learned from cohort studies. Curr Opin Rheumatol. 2014, 26:124-30. PMID: 24419752
  13. Albayda J, Mammen A. Is statin-induced myositis part of the polymyositis disease spectrum? Curr Rheumatol Rep. 2014, 16:433. PMID: 24996782
  14. Mammen A. Necrotizing myopathies – beyond statins. Curr Opin Rheumatol. 2014 Nov;26(6):679-83. PMID: 25203117.
  15. Nance J and Mammen A. Diagnostic Evaluation of Rhabdomyolysis. Muscle and Nerve. 2015; 51:793-810. PMID 25678154.
  16. Michele H and Mammen A. Myositis Mimics. Curr Rheumatol Rep. 2015;17:541. PMID: 26290112
  17. Tiniakou E and Mammen A. Idiopathic inflammatory myopathies and malignancy: A comprehensive review. Clinical Reviews in Allergy and Immunology, epub ahead of print, 2015. PMID: 26429706
  18. Mammen A. Statin-associated autoimmune myopathy. New England Journal of Medicine. 2016;374:664-669. PMID: 26886523.
  19. Mammen A. Autoimmune myopathies. Continuum, accepted 2016.
  20. Pinal-Fernandez I and Mammen A. Spectrum of immune mediated necrotizing myopathies and their treatments. Current Opinion in Rheumatology, accepted 2016.

Case Reports

  1. Leung D, Taylor H, Lindy A, Basehore M, and Mammen A. A case of progressive quadriceps weakness and hyperCKemia mimicking inclusion body myositis. Arthritis Care Res (Hoboken). 2013 [Epub ahead of print] PMID: 24022920.
  2. Nichols L, Pfeifer K, Mammen A, Shahnoor N, and Konersman C. An Unusual Case of Statin-Induced Myopathy: Anti-HMGCoA Necrotizing Autoimmune Myopathy. J Gen Intern Med. 2015 Apr 9. [Epub ahead of print].

Book Chapters

  1. Mammen A, Huganir R. Regulation of NMDA receptor by protein phosphorylation. The ionotropic glutamate receptors. Eds.: DT Monaghan and RJ Wenthold. Humana Press Inc., Totowa, NJ (1997).
  2. Mammen A and Lesser R. Status Epilepticus. The Osler Medical Handbook. Eds.: A Cheng and A Zaas. Mosby, Philadelphia, PA (2003).
  3. Mammen A. Myopathy in scleroderma. Scleroderma. Eds.: Varga, J., Denton C, and Wigley F. Springer (2012).
  4. Mammen A, Truong A, and Christopher-Stine. Dermatomyositis, polymyositis, and immune-mediated necrotizing myopathy. Rheumatology: Current Diagnosis and Treatment. Eds.: J Imboden, D Hellman and J Stone. McGraw-Hill Education (2013).
  5. Mammen A and Amato A. Inflammatory Myopathies. Evaluation and Treatment of Myopathies. Eds. Ciafaloni E, Chinnery P, and Griggs R. Oxford University Press (2014).
  6. Mammen A. Autoimmune muscle disease. Handbook of Clinical Neurology. Eds. Pittock SJ and Vincent A. Elsevier (2016).

Editorials

  1. Mammen A and Chaudhry V. The difficulties of diagnosing neuromuscular complications. The Journal of Supportive Oncology, 2005, 3:285-286.
  2. Mammen A. Clin Chem, 2015, 61:1136.
  3. Mammen A and Sartorelli V. IL-6 blockade as a therapeutic approach for Duchenne muscular dystrophy. EBioMedicine. 2015, 2(4):274-5.

Letters, correspondence

  1. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, and Christopher-Stine L. Rituximab therapy for myopathy associated with anti-srp antibodies: A case series: Authors reply. Arthritis Care and Research. 2011; 63: 461.

Podcasts

  1. August 27, 2010, “A novel autoantibody in patients with necrotizing myopathy”, AANEM Physician Podcast.
  2. May 8, 2012, “A case of necrotizing myopathy with proximal weakness and cardiomyopathy” AAN Neurology Podcast
  3. December 4, 2014, “Antisynthetase syndrome and myositis”, AANEM Physician Podcast.
  4. December 11, 2014, “Necrotizing Myopathies”, AANEM Physician Podcast.
  5. December 18, 2014, “Dermatomyositis and Autoantibodies”, AANEM Physician Podcast.
  6. May 5, 2015, “Immune-mediated necrotizing myopathy”, AAN Neurology Podcast.
  7. May 12, 2015, “Dermatomyositis”, AAN Neurology Podcast.
  8. May 19, 2015, “Inclusion body myositis”, AAN Neurology Podcast.
  9. May 26, 2015, “Immunotherapy for the immune-mediated myopathies”, AAN Neurology Podcast.
  10. September 8, 2015, “Presentation and acquired causes of rhabdomyolysis”, AANEM Physician Podcast.
  11. October 10, 2015, “Inherited etiologies of rhabdomyolysis”, AANEM Physician Podcast.

USE OF THIS SITE

All information contained within the Johns Hopkins Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.